Ipratropium

short-acting quaternary ammonium antimuscarinic (anticholinergic)

Also sold as Atrovent, Nasal spray.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Ipratropium has almost no classical depletion machinery. It is a quaternary ammonium, so it is poorly absorbed: about 7% of a nebulized 2 mg dose reaches the circulation [1], oral absorption is about 2 to 3% and less than 20% of an intranasal dose is absorbed through the nasal mucosa [3], and most of an inhaled metered dose lands in the gut rather than the lung [2]. Plasma levels after inhalation are in the picogram range (steady-state peak 82 +/- 39 pg/mL on 336 mcg/day [2]). It is partially metabolized by ester hydrolysis to inactive products, about half of an intravenous dose is excreted unchanged in urine [2][3], and none of the three labels read mentions a CYP enzyme, a vitamin, a mineral or any dietary interaction [1][2][3]. The drug's local effects (dry mouth, nasal dryness, epistaxis) are intended or adverse pharmacology, not nutrient findings, and they are kept separate from nutrient entries below.

short-acting quaternary ammonium antimuscarinic (anticholinergic) · ATC R03BB01 (inhalation) and R01AX03 (nasal) (WHO ATC/DDD Index [4][5]) · also sold as Atrovent and Atrovent HFA [6]; generic nebulizer solution and nasal spray · reviewed 2026-10-07. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Ipratropium in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Carnitine: OCTN2 interaction in vitro, concentration gap of roughly a million-fold

Yellow — Low

See study details

Ipratropium interacts with the carnitine transporter OCTN2 in cell and structural studies, but the concentrations needed are far above human plasma levels, and no study measured carnitine in ipratropium users.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

Null findings: Davies 2025 [9] saw no transport of ipratropium (disputing [7]); Rotoli 2020 [8] notes prior work in which L-carnitine did not alter ipratropium transepithelial transport. Concentration gap (my arithmetic, using a cation molecular weight of 332.5): the label steady-state peak of 82 pg/mL is about 0.25 nM, so 200 uM [8] is about 8 x 10^5 times higher and the IC50 of 615 uM [9] is about 2.5 x 10^6 times higher. Local airway lining concentrations after inhalation were not found.
At-risk subgroups: Not defined. People with primary carnitine deficiency or OCTN2 variants are a theoretical sensitivity group but no source links them to ipratropium.

Direction

Hypothetical interference with carnitine uptake (depletion direction). Not demonstrated in any living system with clinically relevant exposure.

Regulatory status

Carnitine and OCTN2 are not mentioned in the labels read [1][2][3].

Population evidence

None in humans. Tier B, ipratropium-specific, in vitro or structural: Nakamura 2010 [7] (abstract via OpenAlex): ipratropium uptake in BEAS-2B bronchial epithelial cells was saturable (Km 78.0 uM), OCTN1 and OCTN2 expressed, HEK293 transfectants Km 444 uM (OCTN1) and 53.0 uM (OCTN2), OCTN2 knockdown reduced uptake to 14.8% of control. Rotoli 2020 [8] (full text read through PLOS page): 200 uM ipratropium inhibited L-carnitine uptake on the basolateral side of primary human airway epithelium (EpiAirway, n=3) and Calu-3 cells (n=4) and had no effect on the apical side; percent inhibition is only in a figure not readable here. Davies 2025 [9] (full text read through nature.com): cryo-EM structure of human OCTN2 with ipratropium bound in the substrate site; in oocytes ipratropium elicited no current and acted as an inhibitor of carnitine transport, IC50 615 +/- 174.5 uM (n=5). A 2015 HeLa study listed ipratropium among inhibitors of OCTN1 transport [10] (PubMed listing text only).

Mechanism

Named: competition for the OCTN2 carnitine binding site. Carnitine carries long-chain fatty acids into mitochondria. Whether plasma or tissue carnitine would fall in humans is unmeasured.

Counter-evidence held on record

Counter-evidence The IC50 is millions of times the human plasma peak, the substrate and transport findings conflict between [7] and [9], no human carnitine level was found, and absorption is 7% or less. This is the kind of in vitro transporter interaction that exists for many drugs without any clinical consequence. Framing caution This is a mechanistic note, not a deficiency claim. Do not recommend carnitine supplementation or describe ipratropium as lowering carnitine.

Dietary intake via dry mouth: association with food avoidance, no nutrient measured

Yellow — Low

See study details

One geriatric survey associated inhaled ipratropium with dry mouth, low salivary flow and food avoidance, while physiologic studies found no salivary suppression from inhaled doses; no nutrient or intake quantity was measured.

Full detail and limits

Limits on what this shows

Null findings: PubMed listing summaries (abstracts not opened as records): ipratropium delivered orally by metered-dose inhaler did not significantly reduce salivary flow versus placebo in normal subjects [15]; inhaled ipratropium up to 2.4 mg did not change stimulated salivary secretion while 0.28 mg IV did [16]; a tiotropium review reports xerostomia was more common with tiotropium than with ipratropium [17].
At-risk subgroups: Older adults, nursing-home residents, people also taking other anticholinergic drugs (additive effect, label [2]), and nebulizer users at high total daily dose.

Direction

Reduced intake (mechanism class H). This is a food-choice and chewing context flag. Dry mouth and food avoidance are outcomes, not a nutrient deficiency (Hard Rule 2).

Regulatory status

Dry mouth is labeled: HFA 12-week trial 4% (n=243) versus 2% placebo (n=128), 1-year open-label 2% [2]; nebulizer solution 3.2% (n=219) in a 12-week trial, and more frequent at total daily doses of 2,000 mcg or more [1]; nasal spray under 2% [3]. Taste perversion 0.9% (HFA drug-related) [2]. Nausea 4% HFA versus 2% placebo [2]. No nutrient statement in any label.

Population evidence

Loesche 1995 [14] (abstract via OpenAlex): cross-sectional survey of 529 people over 56 (VA dental clinic 208, retirement home 114, long-term care 132, acute neurological ward 75). About 72% reported xerostomia; stimulated salivary flow was lower in those complaining of xerostomia; xerostomia was associated with avoiding crunchy and sticky foods. The abstract states inhaled ipratropium (with triamcinolone) could be statistically associated with xerostomia, low salivary flow and/or food avoidance, but gives no effect size, odds ratio or p-value, and the ipratropium cell size is unknown. Tier A design with this drug in the cohort, but the outcome is not a nutrient.

Mechanism

Present: muscarinic blockade of salivary glands. Systemic exposure is low, and the effect may be topical, which the survey authors raise.

Counter-evidence held on record

Counter-evidence and confounding Confounding by indication and age is presumed: elderly COPD patients with polypharmacy have dry mouth and poor intake from many causes. The survey cannot separate ipratropium from triamcinolone or from the other xerogenic drugs it names (amitriptyline, oxybutynin, triazolam) [14]. Label rates are small and close to placebo. Framing caution This is an oral-comfort and intake monitoring prompt, not a nutrient deficiency claim. No nutrient supplement is recommended by this entry.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden: rat ischemia/reperfusion model, muscarinic route, mitochondrial readout unretrieved

Yellow — Low

See study details

In rat heart and myocyte models of ischemia/reperfusion, ipratropium given at reperfusion worsened injury, and a mitochondrial membrane readout was taken, but its result could not be retrieved.

Full detail and limits

Limits on what this shows

Null findings: LDH, oxidative stress markers and ATP are not reported in the abstract [12]; their absence is a retrieval limit, not a negative result.

Direction

Drug toxicity in an injury model, not a nutrient finding (Hard Rule 2). Included because the mitochondrial category must be searched directly.

Regulatory status

No mitochondrial statement in the labels [1][2][3]. The HFA label reports supraventricular tachycardia and atrial fibrillation hospitalizations in 0.5% of COPD patients on ipratropium CFC in a 5-year placebo-controlled trial [2], which is a clinical cardiac outcome and not evidence of mitochondrial injury.

Population evidence

None in humans. Harvey 2014 [12] (abstract via OpenAlex and the OUP page; full text paywalled): adult male Sprague-Dawley rat hearts and primary ventricular myocytes under simulated ischemia/hypoxia; ipratropium 10^-11 to 10^-4 M at reperfusion significantly increased infarct/risk ratio (control 51.8 +/- 3.0%, n=6) and reduced cell viability dose-dependently, with more necrosis, apoptosis and cleaved caspase-3. Mitochondrial responses were assessed by TMRM fluorescence and myocyte contracture, but the abstract reports no direction or size. Tier B, ipratropium-specific.

Mechanism

Muscarinic: exogenous acetylcholine (10^-7 M) was protective alone and prevented the exacerbation by ipratropium, and atropine (10^-7 M) produced similar injury. This points to loss of cholinergic protection, not direct mitochondrial toxicity of the molecule.

Counter-evidence held on record

Counter-evidence Effect appears only when ipratropium is added to an ischemia/reperfusion insult, at concentrations that include values far above human plasma levels, and the atropine comparison shows a class pharmacology effect. The authors themselves describe it as nonclinical. Framing caution Not a statement that ipratropium damages mitochondria in patients. Not a basis for any supplement recommendation.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress: reduced tolerance to oxidative stress in rat myocytes (thesis abstract), human markers null or confounded

Yellow — Low

See study details

A doctoral thesis abstract reports that ipratropium reduced the tolerance of rat cardiac myocytes to oxidative stress after simulated ischemia/reperfusion; no study showed a change in a systemic oxidative marker in people given ipratropium, and one direct human exposure study found none.

Full detail and limits

Limits on what this shows

Null findings: Nowak 2001 [22], above. Human COPD studies in which ipratropium was background therapy cannot isolate it: Kuleci 2008 [23] (PubMed record opened; 58 stable COPD patients and 30 healthy controls, 15-day single-blind randomized comparison of placebo, oral methylprednisolone 40 mg/day and NAC 600 mg/day, all on regular ipratropium; plasma MDA fell significantly only in the methylprednisolone group, P = 0.004, and erythrocyte SOD did not differ, so the ipratropium-plus-placebo group showed no significant MDA fall, with no unexposed comparator and group sizes not given in the record); van Beurden 2003 [24] (PubMed record opened; 25 hospitalized COPD patients on IV dexamethasone and nebulised salbutamol/ipratropium; exhaled H2O2 did not change significantly over the stay, values not reported); Orhan 2003 [25] (abstract opened on a repository page; 52 enrolled, 36 completed, acute COPD exacerbation; all received inhaled ipratropium with salbutamol, theophylline, antibiotics and N-acetylcysteine; MDA fell from 2.96 +/- 1.40 to 1.93 +/- 0.63 umol/L and SOD and GSH-Px rose with treatment, p < 0.05, which reflects recovery from the exacerbation and the other drugs and says nothing specific to ipratropium). The ergothioneine transporter did not take up ipratropium [11].
At-risk subgroups: Not defined. The thesis abstract suggests a theoretical sensitivity with concurrent ischemic heart disease, which it says affects about 22% of COPD patients [21]; this is a cardiac-safety question and not a nutrient finding.

Direction

Hypothetical increased susceptibility to oxidative injury in an injury model. This is drug toxicity or pharmacology in a stressed tissue, not a nutrient or antioxidant deficiency (Hard Rule 2), and no antioxidant nutrient was measured.

Regulatory status

No oxidative stress or antioxidant statement in the three labels read [1][2][3].

Population evidence

Tier B, ipratropium-specific, animal: Harvey 2015 doctoral thesis [21] (PDF opened through the fetch tool, but only the front matter and introduction were returned; the results chapters were not). Its abstract states that in 3-month-old Sprague-Dawley rat hearts ipratropium after simulated ischemia/reperfusion produced more infarction, apoptosis and necrosis and "a loss of resilience of oxidative stress"; that acetylcholine and cyclosporin A limited the injury; that the author proposes a link between muscarinic signalling and the mitochondrial permeability transition pore; and that in aged hearts the effect on tolerance of oxidative stress was not significant. The thesis methods describe TMRM-loaded myocytes under laser-induced oxidative stress with time to depolarisation and hypercontracture as readouts, tested with ipratropium 1 x 10^-7 M; the times, effect sizes, n and p values were not retrievable. Human, Tier A design with ipratropium in the cohort and an oxidative marker measured: Nowak 2001 [22] (PubMed record opened): 58 healthy volunteers; exhaled breath condensate H2O2 and TBARs; the record states that moderate exercise, one puff of salbutamol and ipratropium did not significantly change H2O2 or TBARs (ipratropium dose and number of subjects exposed not given in the record). This is a short-term exposure null, not a long-term user study.

Mechanism

Named in the animal work: loss of muscarinic (acetylcholine) cardioprotection with an mPTP-linked mitochondrial route, per the thesis abstract [21]. The same mechanism and source underlie the Mitochondrial burden entry (see Overlap map). Absent for the systemic circulation: plasma levels are about 0.25 nM and absorption is 7% or less [1][2].

Counter-evidence held on record

Counter-evidence The animal effect appears only when ipratropium is added to an ischemia/reperfusion or laser oxidative insult, atropine and loss of acetylcholine protection reproduce it (a class muscarinic effect), the thesis is not peer reviewed in this form, and the numbers behind the abstract statement were not read. The one human exposure study found no change in exhaled H2O2 or TBARs. The COPD treatment studies are confounded by corticosteroids, N-acetylcysteine and disease recovery. Framing caution Not a statement that ipratropium raises oxidative stress or depletes antioxidants in patients. Do not use this entry to suggest an antioxidant supplement.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No study connected ipratropium to copper absorption, chelation or status.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C evidence and no circulating copper claim found. Kept independent of Iron (Hard Rule 7). Not a finding of safety.

What was searched

PubMed listing "ipratropium copper": 1 result, an analytical-chemistry paper (copper oxide electrode for quantifying ipratropium and salbutamol, PMID 42740628), not a biological finding. Three labels read: no copper content [1][2][3]. Drugs.com food-interaction page: none [19].

Channel outcomes

One clean PubMed zero for the biology. Repair pass 2026-10-08: WebSearch "ipratropium copper zinc serum levels COPD patients trace elements bronchodilator" returned only COPD copper-to-zinc disease studies; the one with an abstract opened (acute COPD exacerbation, 30 patients, 20 controls, serum copper 107.5 +/- 20.8 versus 121.5 +/- 23.5 ug/dL in the stable phase) names no ipratropium or any treatment, so it is not evidence for this drug and is not cited. Chelation-style PubMed phrasings were not re-run. Mostly a genuine gap with a residual tooling limit.

Iron

Not graded — disclosed evidence gap

See study details

No study connected ipratropium to iron absorption or iron status; nasal epistaxis is a labeled outcome but nothing links it to iron.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C source links ipratropium to iron and no circulating claim was found. Epistaxis is not iron deficiency (Hard Rule 2) and is not converted into a mechanism here. Kept independent of Copper (Hard Rule 7).

What was searched

PubMed listing "ipratropium iron": 3 results (cough clearance in COPD, a gastroparesis and thyroxine case report, inhaled morphine in cystic fibrosis), none about iron. Labels [1][2][3] contain no iron statement. The nasal label reports epistaxis 9.0% versus 4.6% vehicle (a footnote gives 7.0% versus 2.3%) and discontinuation 0.3% [3]; epistaxis is an adverse outcome and no iron or blood-loss quantity was reported.

Channel outcomes

Clean PubMed zero for iron. Repair pass 2026-10-08: PubMed "ipratropium AND (ferritin OR anemia OR iron deficiency)" returned 3 records (inhaled morphine in cystic fibrosis with iron-deficiency anemia only in the history; a lactic acidosis case with "no anemia" noted; sickle cell airway obstruction with no hemoglobin or iron outcome), none measuring iron status in ipratropium users. Two WebSearch phrasings (ipratropium iron deficiency anemia ferritin) returned only general iron deficiency reviews. Two further PubMed listing attempts were rate limited (429) and not retried. Genuine gap for iron with a small tooling residue.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No study isolated an effect of ipratropium on gut microbiome composition or diversity.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met in substance: no Tier B or C evidence shows an ipratropium effect on microbiota, and no circulating claim was found. The only study with the drug in the cohort cannot separate its effect. Not a finding of safety.

What was searched

PubMed listing "ipratropium microbiome": 1 result [18] (abstract via PubMed record summary). Retrospective study of prospectively collected data, 118 COPD inpatients (2020 to 2022): control group (n=59) budesonide plus ipratropium; observation group (n=59) the same plus probiotics. Lactobacilli and bifidobacteria rose in both groups, Enterobacteriaceae and Enterococcus fell in the observation group versus its own baseline. There was no unexposed comparator, the regimen was combined with budesonide and hospital care, and the abstract does not compare control-group microbiota with the observation group. It cannot attribute any change to ipratropium. Label note: most of an inhaled metered dose deposits in the gut [2], which is exposure, not an effect.

Channel outcomes

One PubMed phrasing completed. Repair pass 2026-10-08: PubMed "ipratropium AND (dysbiosis OR 16S OR gut microbiota OR fecal microbiota)" returned the same single record [18] (all 118 patients received ipratropium; no ipratropium-free arm). A WebSearch for ipratropium gut microbiota 16S COPD returned general COPD gut-microbiota reviews (one PMC review was bot-challenged and not read). The Maier 2018 screen of non-antibiotic drugs against gut bacteria [26] was opened as a full-text PDF and does not name ipratropium. Full text of [18] not opened. Genuine thin literature.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization: in vitro red-cell eryptosis at 1 nM, no human hemoglobin data

Yellow — Low

See study details

At 1 nM for 48 hours, ipratropium triggered calcium entry, shrinkage, phosphatidylserine exposure and slight hemolysis in isolated red cells; no study measured hemoglobin or red-cell mass in ipratropium users.

Full detail, limits and 1 references

Limits on what this shows

Null findings: No human hemoglobin or hematocrit study of ipratropium alone was located. A PubMed listing for ipratropium and hemoglobin returned only the eryptosis paper and unrelated records; one veterinary study (horses with COPD, arterial oxygen pressure improved in recovery, PMID 9952325) reflects bronchodilator pharmacology and is not used [20].

Direction

Hypothetical reduction in red-cell survival. Anemia would be an outcome, and its causes are not nutrient deficiency (Hard Rule 2). Ipratropium's intended bronchodilation is not an oxygen-delivery deficiency.

Regulatory status

No hematologic warning in the three labels read [1][2][3].

Population evidence

None in humans. Shaik 2012 [13] (abstract via OpenAlex): erythrocytes exposed to 1 nM ipratropium bromide for 48 hours; Fluo3 calcium rose, forward scatter fell (shrinkage), annexin-V binding rose, hemolysis (hemoglobin release) rose slightly but significantly. Removing extracellular calcium or blocking cation channels with amiloride (1 mM) nearly abolished phosphatidylserine exposure. Tier B, ipratropium-specific.

Mechanism

Named: calcium entry through cation channels triggering eryptosis. 1 nM is about 4-fold above the label's steady-state plasma peak of about 0.25 nM (my arithmetic, cation weight 332.5), so exposure is within an order of magnitude but over a 48-hour incubation with a constant dose, unlike plasma kinetics (half-life about 2 hours).

Counter-evidence held on record

Counter-evidence Eryptosis in a dish is common for many drugs and is not shown to cause anemia. The abstract does not state whether the concentration matches in vivo exposure, and the full text was not opened. Framing caution Not a claim that ipratropium lowers oxygen-carrying capacity. Do not use this entry to suggest iron, B12 or any supplement.

Effects of inhaled dry powder ipratropium bromide on recovery from exercise of horses with COPD. Equine Vet J 1999. PMID 9952325. — Veterinary study. Seen only as a PubMed search-listing summary.Not opened as a record. Not used for any grade; pharmacologic bronchodilator context only.

ATP production

Not graded — disclosed evidence gap

See study details

No evidence on ipratropium and cellular ATP synthesis or energy output was retrieved.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C evidence on ATP output and no circulating "low energy" claim found. The carnitine and mitochondrial entries are not borrowed here (see Overlap map). Kept independent of Mitochondrial burden and Oxygen delivery/utilization (Hard Rule 7).

What was searched

PubMed listings "ipratropium ATP" (3 results: a trial-listing guide, an OCTN1 transport study in which ATP is only a transport-assay condition [10], and an MRP1 efflux transport study in bronchial cells, none measuring ATP production) and "ipratropium mitochondria" (5 results; see Mitochondrial burden). The Harvey rat study [12] did not report ATP in its abstract.

Channel outcomes

Repair pass 2026-10-08: PubMed "ipratropium respiration" (339 results, first 10 reviewed, all clinical respiratory-medicine records, none measuring ATP or mitochondrial function); a combined respiration, oxidative phosphorylation, membrane potential and oxygen consumption query returned the PubMed home page instead of results and was not repeated; WebSearch "ipratropium bromide mitochondrial respiration ATP oxidative phosphorylation" returned only drug monograph pages. The Harvey 2015 thesis [21] was opened: it reports TMRM depolarisation timing (a membrane potential readout, which belongs to the Mitochondrial burden entry) and no ATP measurement for ipratropium. Genuine gap with a small tooling residue.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

None located
Where it comes from: No consumer or practitioner page listing an ipratropium nutrient depletion was found. Drugs.com food-interaction page lists none [19]. The Antidote Research drug page paths tried (ipratropium, ipratropium-bromide, atrovent) returned 404.
Why it fails: There is nothing to rebut. This is a disclosed absence, not proof that no claim exists: WebSearch was exhausted, so the consumer-claim audit was limited to direct page fetches. The 2026-10-08 repair pass ran WebSearch phrasings for ipratropium with oxidative stress, iron, copper, microbiome and ATP and surfaced no consumer depletion claim, though the search tool returns few commercial pages. Re-check periodically, including claims on mitochondria, antioxidant depletion and dry-mouth nutrition. Dry mouth and nasal dryness are labeled adverse effects, not nutrient claims.

How the body handles this medication

Metabolism and enzymes: Partially metabolized by ester hydrolysis to inactive products (tropic acid and tropane). No CYP enzyme is named, and no induction or inhibition is described in the labels read. No specific pharmacokinetic drug interaction studies were done.[2][3] Atrovent HFA and nasal labels, 12.3 and interactions
Systemic absorption: Nebulized 2 mg: mean 7% absorbed systemically [1]. Inhaled HFA: not readily absorbed from lung or gut; steady-state peak 82 +/- 39 pg/mL, trough 28 +/- 12 pg/mL on 4 inhalations four times daily [2]. Oral absorption about 2 to 3%; nasal absorption below 20% of an 84 mcg per nostril dose [3].[1][2][3]
Elimination: About one-half of an IV dose excreted unchanged in urine. Terminal half-life about 1.6 to 2 hours. Renal clearance 1,019 mL/min of total 2,505 mL/min (nasal label). Pediatric patients 6 to 18 years excrete 8.6 to 11.1% unchanged versus 3.7 to 5.6% in adults.[1][2][3]
Distribution and transport: Plasma protein binding 0 to 9% in vitro. In cell and structural work it interacts with the carnitine transporter OCTN2 and with OCTN1 (see the carnitine entry). It is not transported by the ergothioneine transporter [11].[2][7][8][9][11]
Renal and hepatic impairment: Not studied in renal or hepatic insufficiency; caution is advised [1][2]. No accumulation data are available.[1][2]
Food, antacid and mineral interactions: None listed in any label read. Additive effects with other anticholinergic drugs are the only listed interaction. A consumer interaction database lists no known food interactions (Tier D, context only).[1][2][3][19]
Mechanism screen (Step 2): A absorption interference: absent, no mineral or chelation interaction found. B enzyme induction: absent. C renal wasting: absent. D cofactor antagonism: absent (carnitine transporter interaction is in vitro only). E mitochondrial: animal ischemia/reperfusion data only. F hormonal: absent. G microbiome: not demonstrated. H changed intake: present as dry mouth and food avoidance (nutrient unmeasured). I demand: absent.Author synthesis of [1] to [18]
Local effects with dosing context: HFA 12-week COPD trial: dry mouth 4% (HFA, n=243) versus 2% placebo (n=128). Nasal 0.03% spray versus vehicle: epistaxis 9.0% versus 4.6% (a label footnote gives 7.0% versus 2.3%), nasal dryness 5.1% versus 0.9%, dry mouth or throat under 2%.[2][3]

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

Symptoms / oral health
Dry mouth and eating
Worth asking about dry mouth, chewing or swallowing difficulty and food avoidance in older adults and those on nebulizer doses of 2,000 mcg per day or more or on other anticholinergics [1][2][14]. This is a monitoring prompt, not a finding of an ipratropium nutrient deficiency.
Nasal spray
Epistaxis and nasal dryness
Epistaxis 9.0% versus 4.6% and nasal dryness 5.1% versus 0.9% on the 0.03% spray [3]. Recurrent bleeding warrants clinical review. A CBC and ferritin are reasonable only if bleeding is persistent or symptoms of anemia occur; no iron effect of ipratropium itself is documented.
Lab / only if prompted
Hemoglobin, carnitine
No routine laboratory monitoring for nutrients is supported by the evidence for ipratropium. Hemoglobin and carnitine are not recommended routinely on the basis of the yellow entries here [12][13].
Renal / hepatic
Impairment
Pharmacokinetics were not studied in renal or hepatic insufficiency, so caution is advised [1][2]. About half of an IV dose is excreted unchanged in urine [2][3].
Timing
Supplement separation
No separation interval or mineral, vitamin or food interaction is listed in the labels read [1][2][3]. No supplement dose is recommended or appears anywhere in this dossier, so no upper-limit comparison was needed.
Special populations
Pregnancy, pediatrics
The nasal spray is labeled for ages 6 and older, and children excrete more unchanged drug in urine (8.6 to 11.1% versus 3.7 to 5.6% in adults) [3]. Pregnancy nutrient considerations were not assessed from the label sections retrieved. Elderly dry-mouth risk is covered above.

Overlap map, to prevent double counting

Carnitine
Shares evidence with: Oxidative stress; Mitochondrial burden; ATP production (ungraded)
Note: Carnitine moves fatty acids into mitochondria, a hypothetical bridge to energy metabolism that is not claimed. The OCTN transporter family is the common topic: [7][8][9] (carnitine entry), [10] (OCTN1, cited in the ATP entry as a non-ATP-production result) and [11] (the ergothioneine transporter, a null cited under oxidative stress). They are different transporters and different findings; do not count them as repeated confirmation.
Mitochondrial burden
Shares evidence with: ATP production (ungraded); Oxidative stress
Note: The Harvey rat study [12] appears in the mitochondrial entry and as a source whose ATP readout was not reported. The same laboratory program (Harvey 2014 paper [12] and the Harvey 2015 doctoral thesis [21]; whether they share an identical dataset was not confirmed, so treat them as one source family) supports the oxidative stress entry through its oxidative-stress tolerance finding. One research program, not independent lines of evidence.
Oxidative stress
Shares evidence with: Mitochondrial burden; Carnitine (null [11])
Note: Animal evidence is the Harvey program [12][21], shared with Mitochondrial burden. The human oxidative-marker studies [22][23][24][25] are separate from it and mostly null or confounded. The ergothioneine null [11] is a transporter result, not an oxidative marker.
Oxygen delivery/utilization
Shares evidence with: Iron (ungraded)
Note: No shared source. Any anemia would be an outcome and is not double counted.
Dietary intake via dry mouth
Shares evidence with: Fails verification (none located)
Note: The intake entry rests on [14] plus labels and is an intake context flag, not a nutrient claim.
All entries
Shares evidence with: Labels [1][2][3]
Note: All pharmacokinetic and adverse-event figures come from the same three labels; they are one regulatory source family, not independent confirmation.
Copper; Iron
Shares evidence with: none
Note: Graded separately per Hard Rule 7; no shared source.

All references used above

Ipratropium

Findings for this medication

What the research found

Carnitine: OCTN2 interaction in vitro, concentration gap of roughly a million-fold

Dietary intake via dry mouth: association with food avoidance, no nutrient measured

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden: rat ischemia/reperfusion model, muscarinic route, mitochondrial readout unretrieved

💥Oxidative Stress

Oxidative stress: reduced tolerance to oxidative stress in rat myocytes (thesis abstract), human markers null or confounded

⚖️Copper and Iron Balance

Copper

Iron

🌿Gut Microbiome Risk

Gut microbiome risk

💨Oxygen and ATP Output

Oxygen delivery/utilization: in vitro red-cell eryptosis at 1 nM, no human hemoglobin data

ATP production

Claims checked and not supported

None located

How the body handles this medication

What the research says is worth watching

Overlap map, to prevent double counting

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output